Ovarian Cancer Clinical Trial
Official title:
Does a Post Treatment Survivorship Care Plan Improve Gynaecological Cancer Patient's Quality of Life and Self Efficacy? A Mixed Methods Pilot Study.
After treatment women surviving gynaecological cancer may experience lateeffects and longterm
challenges specific to their disease and treatment resulting in functional deficits and a
reduction in societal integration (Yabroff et al., 2004, Yadav, 2007). The available research
on best models of posttreatment rehabilitation support for women posttreatment for
gynaecological cancer is limited. The primary objective of this study is to determine if
there is any additional benefit, over usual rehabilitation care, of additional rehabilitation
appointments to develop a survivorship care plan on cancer specific health related quality of
life.
Secondary objectives are to determine any additional benefit to general selfefficacy, generic
health related quality of life or social and health economics for patients who have completed
treatment for stage I or II gynaecological cancer. Also to explore the patient's perspectives
of the intervention. The study will be open to patients attending the outpatient
gynaecological clinics of the Royal Marsden NHS Foundation Trust having recently completed
treatment for Stage I or II gynaecological cancer. They will report that they have
experienced a physical or psychosocial need resulting from the disease or its treatment; be
aged over 18 years and be willing and able to articulate their needs. The study will last for
six months for each participant. It will involve completing questionnaires and attending two
extra rehabilitation appointments to develop a survivorship care plan at the hospital may
also include attending for an interview about being involved in the study for those
randomised to the intervention group
Purpose and design We conducted a preliminary qualitative study last year (Rec Ref
10/H0608/56) where gynaecological patients reported unmet rehabilitation care needs, both
physical and psychosocial. At the end of treatment patients said that they were unaware of
how to resolve these needs. They also reported that they wanted support and information to
manage consequences of cancer and treatment themselves rather than become 'overmedicalised'
and require treatment from a professional, if that were possible (Sandsund et al., 2011).
Since there is as yet no body of evidence to prove a best model of delivery we have developed
this study to reflect the intervention participants in the study suggested would best support
them.
During the preliminary study participants made suggestions that may improve their journey
through treatment. Of the five focus groups all suggested a meeting in clinic with a
rehabilitation professional at the end of their treatment to explore their rehabilitation
needs. The intervention was as such described and defined by the patients in the preliminary
study.
After the study was analysed and presented to the Rehabilitation Research Group discussions
started regarding research questions and a design for this interventional study. The Head of
Therapies, a representative from the Psychological Care/ Psychological Support Service and a
Nurse Consultant in Living with and Beyond Cancer have been involved in the development of
the protocol from the preliminary study in order to ensure its' conduct will be feasible
within The Royal Marsden NHS Foundation Trust (RM).
There have been discussions amongst the research group and the authors as to the best way to
clinically screen for physical and psychosocial problems. The FACTG, the EORTC and the
Distress Thermometer were most thoroughly considered. The Distress Thermometer was chosen as
the questions were felt to best cover issues we felt the participant group may have. It has
been used in a National Cancer Survivorship Initiative/ Department of Health project for
which RM was one of the sites. on evaluation of the project it was found to be clinically
useful as a screening tool and was acceptable to our patients.
The European Organisation for Research and Treatment of Cancer Quality of life Questionnaire
- C30 (EORTC QLQC30),General Self Efficacy Scale (GSES), Short Form 36 (SF36) were chosen for
their wide use in rehabilitation intervention studies because of their ability to detect
change over time reliably in cancer populations. We believe that the primary outcome measure
the EORTC will be sensitive enough to detect changes due to the intervention. The
statistician has given advice to this regard and provided the statistical support for the
study to date.
A Health Economist who is involved with other studies at RM has developed the study specific
forms to measure the economic evaluation of impact on health and social care provision. She
will perform the cost analysis of this information to see if the intervention has had any
health or social economic impact. The patient's perspectives of the intervention will be
sought using qualitative interviews for a randomised sample of those completing the study.
This will be used to assess the acceptability of the intervention to patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |